Executive Chairman · X4 Pharmaceuticals, Inc (XFOR)

Adam Craig

FY2025 is the first fiscal year CompBrief holds for Adam Craig as a named executive officer of X4 Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$6,705,205

1st of 4 named executive officers at X4 Pharmaceuticals by FY2025 total.

4 named officers on file for X4 Pharmaceuticals, FY2025

See an example →

What this number hides

The filing gives the total. X4 Pharmaceuticals’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how X4 Pharmaceuticals’s whole pay program stands against its peers

  • X4 Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on XFOR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 20, 2026 (DEF 14A).

Free

Get Adam Craig’s full pay file as a PDF — free

More than this page: up to 10 years of Adam’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Adam Craig and every company like it: Velarion Intel, free for 3 days, no card →

Adam Craig compensation by year

X4 Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as X4 Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$179,629
Bonus$0
Stock awards$0
Option awards$6,410,958
Non-equity incentive$114,479
Pension and deferred compensation$0
All other$139
Total$6,705,205

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: X4 Pharmaceuticals, Inc DEF 14A filed March 20, 2026, accession 0001501697-26-000031, and prior-year filings. Open the filing on EDGAR.

How this page was built: the X4 Pharmaceuticals, Inc filed document, accession 0001501697-26-000031. Every figure is read from that document and cited to the page and table it appears in. Filed March 20, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option1,609,873—$1.42
Option2,329,154—$1.42
Option529,201—$3.14

Per the Outstanding Equity Awards at Fiscal Year-End table in X4 Pharmaceuticals, Inc's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

X4 Pharmaceuticals’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Adam Craig · this pageExecutive Chairman$6,705,205
John VolponePresident and Chief Operating Officer$6,667,487
David KirskeChief Financial Officer, Treasurer and Corporate Secretary$4,599,266
Paula RaganFormer President and Chief Executive Officer$2,640,569

Board service

X4 Pharmaceuticals board · FY2025

How this board is paid

Company policy: X4 Pharmaceuticals pays directors a $40,000 cash retainer. As stated in X4 Pharmaceuticals's FY2025 proxy.

Adam Craig's compensation dossier, X4 Pharmaceuticals

You have read Adam Craig's totals and holdings. The dossier adds each equity grant X4 Pharmaceuticals disclosed for Adam Craig and X4 Pharmaceuticals's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full X4 Pharmaceuticals compensation record

free company brief

This page is one person within X4 Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order X4 Pharmaceuticals's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are X4 Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order XFOR

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Adam Craig's compensation dossier